Investors

VIDA® Diagnostics, a leading developer of quantitative pulmonary imaging software, is supported by revenue, private investment and NIH grants. VIDA received Series A financing in 2007. In December of 2008, VIDA was FDA 510k approved for clinical use in the U.S.

September 2011, the company achieved International Organization for Standardization (ISO 13485) certification and CE certification for its flagship product, Apollo^®. The CE certification permits VIDA to sell Apollo for clinical use in the European Economic Area (EEA) and Switzerland. VIDA is currently pursuing CMDCAS certification for regulatory approval in Canada.

For information on investment opportunities, please contact us via email at investors@vidadiagnostics.com or submit our information request form.

ABOUT VIDA

2012 Annual Meeting of the Society of Thoracic Radiology
March 11-14, 2012
Hyatt Regency Huntington Beach Resort & Spa
Huntington Beach, CA

Visit Meeting Site »

See VIDA at the
ATS 2012 ● The Annual International Conference of the American Thoracic Society.
May 18-23. San Francisco, CA

Visit Meeting Site »

VIDA is both the word “Life” in Spanish and an acronym representing the core mission of our software “Volumetric Image Display and Analysis.” The initial inspiration for the company began 30 years ago when Dr. Eric Hoffman introduced three-dimensional X-ray imaging techniques for the assessment of the lung, in conjunction with Mayo Clinic's ground-breaking Dynamic Spatial Reconstructor. His vision was to utilize the wealth of density information embedded in three-dimensional radiological images to add quantitative, repeatable diagnostic metrics to the visual interpretation of scan images and to provide the link between structure and function.

Site Developer: Phoenix Designs